Initially submitted April 15, 2016 ; accepted for publication July 12, 2016 .
We compared the relative importance of atypical major depressive disorder (MDD), nonatypical MDD, and dysthymic disorder in predicting 3-year obesity incidence and change in body mass index and determined whether race/ethnicity moderated these relationships. We examined data from 17,787 initially nonobese adults in the National Epidemiologic Survey on Alcohol and Related Conditions waves 1 (2001-2002) and 2 (2004-2005) who were representative of the US population. Lifetime subtypes of depressive disorders were determined using a structured interview, and obesity outcomes were computed from self-reported height and weight. Atypical MDD (odds ratio (OR) = 1.68, 95% confidence interval (CI): 1.43, 1.97; P < 0.001) and dysthymic disorder (OR = 1.66, 95% CI: 1.29, 2.12; P < 0.001) were stronger predictors of incident obesity than were nonatypical MDD (OR = 1.11, 95% CI: 1.01, 1.22; P = 0.027) and no history of depressive disorder. Atypical MDD (B = 0.41 (standard error, 0.15); P = 0.007) was a stronger predictor of increases in body mass index than were dysthymic disorder (B = −0.31 (standard error, 0.21); P = 0.142), nonatypical MDD (B = 0.007 (standard error, 0.06); P = 0.911), and no history of depressive disorder. Race/ethnicity was a moderator; atypical MDD was a stronger predictor of incident obesity in Hispanics/Latinos (OR = 1.97, 95% CI: 1.73, 2.24; P < 0.001) than in non-Hispanic whites (OR = 1.54, 95% CI: 1.25, 1.91; P < 0.001) and blacks (OR = 1.72, 95% CI: 1.31, 2.26; P < 0.001). US adults with atypical MDD are at particularly high risk of weight gain and obesity, and Hispanics/Latinos may be especially vulnerable to the obesogenic consequences of depressions. body mass index; depressive disorders; ethnicity; obesity; prospective study; race Abbreviations: BMI, body mass index; MDD, major depressive disorder; NESARC, National Epidemiologic Survey on Alcohol and Related Conditions.
Substantial research has suggested that depression is a risk factor for obesity (1) ; however, little is known about whether the strength of this relationship differs across depressive disorder subtypes. In the present study, we examined the subtypes of atypical major depressive disorder (MDD), nonatypical MDD, and dysthymic disorder. MDD is characterized by a discrete episode of moderate to severe depressive symptoms that lasts at least 2 weeks (2) . Key features of atypical MDD are reversed somatic-vegetative symptoms of hyperphagia (increased appetite/weight gain) and hypersomnia (excessive sleep), whereas nonatypical MDD is a heterogeneous group that includes MDD with other features, such as feeling anxious or melancholic (2) (3) (4) .
In contrast to the episodic nature of MDD, dysthymic disorder is a chronic condition characterized by low-grade depressive symptoms that last at least 2 years (2).
Emerging evidence has suggested that obesity risk may vary across subtypes of depressive disorders, with atypical MDD likely conferring the greatest risk. First, the hyperphagia that accompanies atypical MDD could lead to increased energy intake, and the hypersomnia could result in decreased energy expenditure. Second, atypical MDD has been linked with other obesity-promoting biological and behavioral changes. At the biological level, atypical MDD has been associated with increased systemic inflammation and metabolic dysregulation (5) (6) (7) (8) (9) . At the behavioral level, atypical MDD has been related to poorer diet quality (10) and lower activity levels (4) . Despite this mechanistic rationale and supporting evidence, the only 2 prospective studies in which atypical MDD has been examined as a predictor of obesity outcomes yielded mixed results. On one hand, Lasserre et al. (11) found that Swiss adults with current atypical MDD-but not those with current melancholic, combined, or unspecified MDD-were at greater risk of incident obesity than were adults with no depressive disorder history at 5.5-year follow-up. On the other hand, Lamers et al. (12) examined data from The Netherlands Study of Depression and Anxiety and found that although adults with atypical MDD had higher body mass indices (BMIs; weight in kilograms divided by height in meters squared) at all assessments, the trajectory of BMI change over 6 years did not differ between cases with atypical MDD and nondepressed controls. In fact, participants with melancholic MDD showed greater increases in BMI trajectory.
To date, there has been no study in which investigators examined the associations of depressive disorder subtypes with incident obesity in a US population-based sample or tested whether the strengths of these relationships differ by race/ ethnicity. In our past studies in which we examined the associations of depression with obesity-related factors (systemic inflammation (13) and insulin resistance (14)), we detected important moderation by race/ethnicity. Thus, we utilized data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), a prospective study of adults who were representative of the US population. Our objectives were 1) to compare the relative importance of depressive disorder subtypes in predicting the 3-year incidence of obesity and changes in BMI and 2) to determine whether these relationships are moderated by race/ethnicity.
METHODS

Study design and sample
NESARC is a prospective cohort study designed by the National Institute on Alcohol Abuse and Alcoholism to determine the prevalence of alcohol use disorders and associated disabilities in the US civilian noninstitutionalized population who are 18 years of age or older. NESARC sampling and interview methods have been described previously (15) (16) (17) From the wave-2 cohort, we excluded 9,432 respondents with a wave-1 BMI of 30 or higher. We then excluded 589 respondents with BMIs that were potentially indicative of anorexia (<18.5) and 4,445 older adults (≥65 years of age). Depression and weight loss are both common in adults with anorexia nervosa (18) , and depression has been linked with unintentional weight loss in older adults (19) . Thus, including these groups would likely lead to an underestimation of depression-obesity relationships. Next, we excluded 1,506 women who reported pregnancy during the year before wave 1 or 2 because of pregnancy's potential influence on depression and weight gain (20, 21) . We also excluded 3 respondents with discrepant wave-1 and wave-2 height values, which possibly reflected data entry errors. Finally, we excluded 891 respondents with missing data for included model variables. The characteristics of the final study population (n = 17,787) are shown in Table 1 .
Measures and procedures
Subtypes of lifetime depressive disorder. Lifetime dysthymic disorder and MDD were determined using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV, a fully structured diagnostic interview administered by lay interviewers to assess mental disorders using criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (22) . NESARC personnel coded 2 diagnostic variables for each disorder: past year and before the past year. We used the NESARC MDD variables that excluded illness-induced and substance-induced depressive disorders and ruled out depression due to bereavement (16) . The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV has demonstrated good test-retest reliability for depressive disorders (23) and generally good agreement with clinician evaluations (17) . We computed a 4-level variable for depressive disorder subtypes (no depressive disorder, dysthymic disorder only, nonatypical MDD, and atypical MDD), from which we created 3 indicator variables for which no depressive disorder was the referent. First, respondents were coded as having no depressive disorder if they never met criteria for dysthymic disorder or MDD. Respondents were coded as having lifetime dysthymic disorder if they met diagnostic criteria in the past year or before the past year. The same scheme was used for lifetime MDD. Participants who met the criteria for both lifetime dysthymic disorder and MDD were placed into the MDD group. Next, we further classified respondents with lifetime MDD based on responses to questions that began with, "During that time when your mood was at its lowest/you enjoyed or cared the least about things…" The atypical MDD group consisted of respondents with both hyperphagia and hypersomnia. We coded adults as having hyperphagia if they answered "yes" to either of the questions "…did you gain at least 2 pounds a week for several weeks or at least 10 pounds altogether within a month (other than when you were growing or pregnant)?" or "…did you find that you wanted to eat a lot more than usual for no special reason, most days for at least 2 weeks?" We coded respondents as having hypersomnia if they answered "yes" to the question "…did you sleep more than usual nearly every day for at least 2 weeks?" The nonatypical MDD group consisted of the remaining respondents with lifetime MDD.
Several lines of evidence support the validity of the atypical MDD construct. First, it has long been recognized as an MDD specifier in diagnostic manuals (2, 24) . Second, existing evidence, including results of latent class analyses, has indicated that atypical depression is a clinical entity distinct from other depressive disorder subtypes (25) (26) (27) . Third, although other diagnostic criteria for atypical MDD exist (2, 24) , using only the reversed somatic-vegetative symptoms has been found to be a valid approach (for full atypical MDD definition, 78% sensitivity and 91% specificity) (28) and thus has been used in several prior studies (4, 27, 29, 30) . Obesity outcomes. During wave-1 and wave-2 interviews, respondents self-reported height and weight, from which we computed BMIs. Incident obesity was defined as a wave-2 BMI of 30 or higher. BMI change was calculated as wave-2 BMI adjusted for wave-1 BMI, resulting in a residualized change score. Although measured BMI is more precise, a results from a study of the National Health and Nutrition Examination Survey-III (31) support the use of self-reported BMI in epidemiologic studies in which relationships between factors are examined because high correlations were observed between measured and self-reported BMI in non-Hispanic whites (0.95), non-Hispanic blacks (0.93), and Mexican Americans (0.90).
Covariates. The following demographic variables, assessed via self-report at wave 1, were included as covariates: age, sex, race/ethnicity, and educational level. Because of low counts in some categories, we recoded race/ethnicity into a 4-level variable (non-Hispanic white, non-Hispanic black, Hispanic/Latino, and other) and created 3 indicator variables with non-Hispanic white as the referent. Educational level was assessed by asking participants the highest grade or year of school that they completed. We computed a 4-level variable (less than high school diploma, high school diploma or equivalent, some college or associate's degree, and bachelor's degree or higher), from which we created 3 indicator variables with less than high school diploma as the referent.
The following possible confounders of the depressionobesity relationship, which were assessed at wave 1, were also included as covariates: lifetime alcohol use disorders (32) , lifetime tobacco use (32) , lifetime antidepressant use (33) , and select chronic medical conditions (i.e., cardiovascular disease, liver disease, and arthritis) (34) . We computed a 4-level variable for lifetime alcohol use disorders (no alcohol abuse/dependence, alcohol abuse only, alcohol dependence only, and alcohol abuse and dependence), which we used to create 3 indicator variables with no alcohol abuse/ dependence as the referent. From the NESARC's tobacco use variable (current user, former user, and lifetime nonuser), we created 2 indicator variables with lifetime nonuser as the referent. Lifetime antidepressant use for participants with dysthymic disorder and for those MDD were separately assessed with the same question: "Did a doctor ever prescribe any medicines or drugs to improve your mood or to make you feel better?" Those who answered "yes" to either question were coded as positive for lifetime antidepressant use. Respondents who reported 1) arteriosclerosis, angina, or myocardial infarction; 2) cirrhosis or liver disease; or 3) arthritis in the past year that was confirmed by a health professional were coded as positive for cardiovascular disease, liver disease, and arthritis, respectively.
Data analysis
To compare the relative importance of depressive disorder subtypes in predicting the obesity outcomes, we ran logistic (incident obesity) and linear (BMI change) regression models that were adjusted for demographic characteristics and that were fully adjusted. The reference group in the first set of models comprised persons with no depressive disorder; however, in subsequent models, it was switched so that we could obtain all pairwise comparisons. Covariates in the models adjusted for demographic characteristics were age, sex, race/ethnicity, educational level, and wave-1 BMI.
The fully adjusted models also included alcohol use disorders, tobacco use, antidepressant use, cardiovascular disease, liver disease, and arthritis. To determine whether depression-obesity relationships were moderated by race/ethnicity, we reran the fully adjusted models with interaction terms. From these models, we excluded respondents who were in the "other" race/ ethnicity category or who had dysthymic disorder only because of the small number of incident obesity cases in these groups, leaving a final sample of 16,724 adults. We created 4 interaction terms by multiplying each race/ethnicity indictor variable (non-Hispanic black vs. non-Hispanic white (termed RE1) and Hispanic/Latino vs. non-Hispanic white (termed RE2)) by each depressive disorder subtype indictor variable (nonatypical MDD vs. no depressive disorder and atypical MDD vs. no depressive disorder). These interaction terms were simultaneously entered into the fully adjusted models. Next, to obtain all possible contrasts, we changed the reference group of our race/ethnicity indicator variable (non-Hispanic black vs. Hispanic/Latino (termed RE3)) and repeated the process. Thus, 12 interaction terms were tested: 6 predicting incident obesity and 6 predicting BMI change. When evidence of moderation by race/ethnicity was observed, we ran the fully adjusted models stratified by race/ethnicity.
We conducted sensitivity analyses to assess the influence of a narrower definition of atypical MDD-that is, one that excluded the weight gain criterion-on the results. We coded individuals as having hyperphagia only if they answered "yes" to the Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV question about appetite increases. Although this decreased the number of atypical MDD cases from 528 to 448, it did not change the pattern of results (data not shown).
Analyses were conducted with SAS statistical software, version 9.3 (SAS Institute, Inc., Cary, North Carolina). Models were weighted to account for oversampling, probabilities of selection, and nonresponse (17) . Weighted analyses provide estimates for US civilian noninstitutionalized population based on the 2000 Decennial Census (17) .
RESULTS
Depressive disorder subtypes and obesity outcomes
The rates of lifetime MDD (35) and atypical MDD (27) were consistent with prior estimates (Table 1) . However, the rate of dysthymic disorder was lower (35) , likely because persons with both dysthymic disorder and MDD were placed into the MDD groups. A total of 1,952 (11.0%) cases of incident obesity were identified, and the mean 3-year change in BMI was 0.95. Depression rates and obesity outcomes varied by race/ethnicity (Table 1) , with the highest rates of most depressive disorders in non-Hispanic whites, the highest rate of incident obesity in non-Hispanic blacks, and the greatest BMI change in non-Hispanic blacks and Hispanics/Latinos.
Depressive disorder subtypes predicting obesity outcomes: full sample
In the logistic regression models adjusted for demographic characteristics (Table 2) , dysthymic disorder only (P < 0.001) and atypical MDD (P < 0.001) predicted incident obesity, although nonatypical MDD did not (P = 0.31). In the fully adjusted models, however, all 3 subtypes predicted incident obesity. Compared with persons with no depressive disorder, the odds of incident obesity were 66% greater in respondents with dysthymic disorder only (P < 0.001), 11% greater in those with nonatypical MDD (P = 0.027), and 68% greater in those with atypical MDD (P < 0.001). Models in which we used different reference groups revealed that both dysthymic disorder only (odds ratio = 1.49, 95% confidence interval: 1.15, 1.94; P = 0.003) and atypical MDD (odds ratio = 1.51, 95% confidence interval: 1.26, 1.81; P < 0.001) were stronger predictors of incident obesity than was nonatypical MDD. These models also showed that dysthymic disorder only and atypical MDD did not differ in the odds of incident obesity (odds ratio = 0.99, 95% confidence interval: 0.76, 1.28; P = 0.930).
The linear regression models (Table 3 ) yielded some complementary results, as atypical MDD predicted increases in BMI in the demographic characteristic-adjusted (P = 0.010) and fully adjusted (P = 0.007) models. After adjustment for all covariates, the average BMI of respondents with atypical MDD increased 0.41 more over the 3-year period than did that that of respondents with no depressive disorder. In contrast to incident obesity, dysthymic disorder only (P = 0.134 and P = 0.142) and nonatypical MDD (P = 0.961 and P = 0.911) did not predict BMI change in the demographic characteristic-adjusted or fully adjusted models. Models in which we used different reference groups indicated that atypical MDD was a stronger predictor of BMI change than were dysthymic disorder only (B = 0.73 (standard error, 0.25); P = 0.004) and nonatypical MDD (B = 0.40 (standard error, 0.15); P = 0.009). These models also showed that there was no difference in BMI change between dysthymic disorder only and nonatypical MDD groups (B = −0.32, (standard error, 0.21); P = 0.130).
Depressive disorder subtypes predicting obesity outcomes: stratified by race/ethnicity
We tested 6 interaction terms in fully-adjusted models predicting incident obesity (see the Data Analysis section). Although the nonatypical MDD × RE1 (P = 0.56) and atypical MDD × RE1 (P = 0.76) interactions were not significant, the remaining 4 interactions were significant: for nonatypical MDD × RE2, P < 0.001; for atypical MDD × RE2, P < 0.001; for nonatypical MDD × RE3, P = 0.002; and for atypical MDD × RE3, P = 0.042. Given this evidence of moderation, we ran models stratified by race/ethnicity (Figure 1 ). Atypical MDD predicted incident obesity in all 3 groups. The interaction results indicated that atypical MDD was a stronger predictor in Hispanics/Latinos (97% greater odds) than in non-Hispanic whites (54% greater odds) and nonHispanic blacks (72% greater odds). Nonatypical MDD predicted incident obesity in Hispanics/Latinos but not in non-Hispanic whites or non-Hispanic blacks (Figure 1) . Once again, the interaction results revealed that nonatypical MDD was a stronger predictor in Hispanics/Latinos (36% greater odds) than in non-Hispanic whites and non-Hispanic blacks (no increase in odds).
We tested the same interaction terms in fully adjusted models to predict BMI change. None of the 6 interactions were significant (P > 0.34 for all). Because there was no evidence of moderation by race/ethnicity, we did not run stratified models.
DISCUSSION
In a large sample representative of the US population, we found that lifetime atypical MDD and lifetime dysthymic disorder were stronger predictors of 3-year incidence of obesity than were lifetime nonatypical MDD and no depressive disorder history. Atypical MDD was also a stronger predictor of 3-year increases in BMI than were dysthymic disorder, nonatypical MDD, and no depressive disorder history. To illustrate, adults with atypical MDD had a 68% greater odds of incident obesity and exhibited a 0.41 greater increase in BMI than did those without a depression history. In addition, adults with atypical MDD had 51% greater odds of incident obesity and displayed a 0.40 greater increase in BMI than did those with nonatypical MDD. We detected evidence of moderation by race/ethnicity for incident obesity but not for BMI change. Although atypical MDD predicted incident obesity in all 3 racial/ethnic groups, it was a stronger predictor in Hispanics/Latinos than in non-Hispanic whites and non-Hispanic blacks (97% greater odds versus 54% and 72%, respectively). Nonatypical MDD predicted incident obesity only in Hispanics/Latinos. Our findings indicate that 1) those with atypical MDD are a subgroup of depressed adults with a particularly elevated risk of gaining weight and developing obesity and 2) Hispanics/Latinos may be especially vulnerable to the obesogenic consequences of depression. Our results agree with 1 of 2 existing prospective studies in which researchers compared the predictive utilities of depressive disorder subtypes. In a Swiss sample, Lasserre et al. (11) found that current atypical MDD, but not other MDD subtypes, predicted incident obesity and increases in BMI, waist circumference, and fat mass over 5.5 years. In the present study, we extended their findings to the US population. Our results, however, do not agree with those of Lamers et al. (12) , who found that BMI trajectories over the 6-year follow-up period did not differ between adults with atypical MDD and nondepressed controls. In addition, results from the analysis by Pickering et al. (36) of the NESARC data conflict with ours, because they found that MDD did not predict changes in BMI class over time. However, Pickering et al. did not examine MDD subtypes, which likely obscured relationships. Although a link between atypical MDD and obesity-related variables has been detected in a few cross-sectional studies (29, 37, 38) , the potential for reverse causality (1) limits their usefulness.
Atypical MDD may be a stronger predictor of obesity outcomes for several reasons. First, it is plausible that the symptoms of hyperphagia and hypersomnia lead to increased energy intake and decreased energy expenditure, respectively. Second, patients with atypical MDD have poorer diet quality than do those with melancholic MDD (10), which could result in higher energy intake. Third, adults with atypical MDD report higher rates of disability days and restricted activity days than do those with nonatypical MDD (4), which could lead to lower energy expenditure. Fourth, atypical MDD is characterized by earlier age of onset, more severe symptoms, and a greater number of episodes (4, 30, 39) . Thus, people with atypical MDD have greater exposure to depression and its obesogenic consequences. Fifth, compared with persons with nonatypical depression, those with atypical depression are also more likely to be taking an antidepressant (4), some of which have been linked to weight gain (40) . Sixth, increased systemic inflammation and metabolic dysregulation have been observed in atypical MDD (5-9); however, it is unclear whether these changes are causes or consequences of weight gain. Finally, shared genetic factors could contribute to both future atypical MDD and obesity. As an example, a fat mass and obesity-associated protein (FTO) gene variant was found to be related to greater odds of having atypical MDD (41) .
To our knowledge, we are the first to report that the strength of associations between depressive disorder subtypes and obesity outcomes depends on race/ethnicity, with the strongest relationship found in Hispanics/Latinos. These findings conflict with those from prior prospective studies, in which depression was found to be a more consistent or stronger predictor of obesity outcomes in non-Hispanic whites (42, 43) . A key methodological difference is that our study utilized a US population-based sample, whereas past studies utilized samples of adolescents (42) and older adults (43) , possibly limiting generalizability. Although the mechanisms underlying the stronger relationship in Hispanics/Latinos are unknown, evidence has suggested that depressed Hispanics/Latinos are less likely to engage in physical activity than are depressed non-Hispanic whites (44) , which could promote obesity. Despite limited knowledge about underlying mechanisms, our race/ ethnicity findings are of high potential significance, because the stronger obesogenic consequences of depressive disorders in Hispanics/Latinos could in part explain the health disparity in obesity rates between Mexican Americans (40%) and other Hispanics (39%) compared with non-Hispanic whites (34%) (45) .
Our study has limitations. First, BMI was calculated from self-reported height and weight. Although correlations between measured and self-reported BMI are high, relying on selfreports could result in an overestimation of height and underestimation of weight (31) , leading to missed cases of incident obesity. Such misclassification, however, would reduce power and bias results toward the null hypothesis. Second, although we adjusted for lifetime antidepressant use, we could not examine specific medications. Some antidepressants (e.g., selective serotonin reuptake inhibitors) (46, 47) are more likely to promote weight gain. Third, we attempted to exclude respondents with a BMI that was potentially indicative of anorexia (<18.5); however, we could not exclude people with or adjust for eating disorders because they were not assessed in NESARC.
To summarize, our findings from a large US populationbased sample suggest that adults with lifetime atypical MDD are at a particularly high risk of gaining weight and developing obesity and that Hispanics/Latinos may be especially vulnerable to the obesogenic consequences of depressive disorders. Our results have implications for research and clinical practice. Regarding research, investigators conducting intervention studies in which they seek to prevent depression-related obesity may want to specifically target patients with atypical MDD. In addition, researchers attempting to address racial/ethnic disparities in obesity rates in intervention studies should consider evaluating the effect of depression treatment on closing these gaps. Concerning practice, clinicians who see depressed patients who have reversed somatic-vegetative symptoms or who are Hispanic/ Latino may want to closely track weight changes, consider weight-related side effects when selecting antidepressants, and initiate weight loss interventions when indicated.
